Akcea Therapeutics Inc. (NASDAQ:AKCA) has completed its Phase 1/2 clinical study of AKCEA-APOCIII-LRx have turned to be positive. The results presented at the American College of Cardiology (ACC) Annual Scientific Session have continued encouraging compliments given that it will be a solution designed to reduce the production of apolipoprotein C-III, or apoC-III.
The study sampled 67 healthy volunteers and patients treated with multiple doses of AKCEA-APOCIII-LRx. After six weeks of treatment, the results indicated dose-dependent reductions in ApoC-III protein of up to 80%. However, even after the discontinuation of the treatment, there were no reports of adverse events and neither were there hepatic or renal signals.
AKCEA-APOCIII-LRx moves to the Phase 2 clinical study of investigation
The outcome of Phase 1/2 clinical study is encouraging according to the chief medical officer at Akcea Therapeutics, Dr. Louis O’Dea. He writes, “The data showing significant and sustained reductions of multiple parameters, including ApoC-III and triglyceride levels, underscore the important regulatory role ApoC-III protein plays in controlling lipid levels in blood”.
The success of Phase 1/2 clinical study now introduces AKCEA-APOCIII-LRx to a Phase 2 clinical study, which will take on board close to 100 patients. The study will be evaluating not only the efficacy of the drug but also its dosing frequencies and will involve a majority of those suffering from the established cardiovascular disease (CVD).
Akcea creates collaboration with Ionis
In an effort to strengthen its ability to move to the next level of success, Akcea has established a collaboration with Ionis Pharmaceuticals. The primary role of the agreement, which is worth $1.7 billion is to push forward the planned mid-2018 inotersen launch. According to the chief executive officer and chairman of Ionis, Stanley T. Crooke, the collaboration will give the business more confidence and strategies of commercializing the drug. Other benefits from the collaboration include the maximization of the commercial value of inotersen.
The inotersen commercial team is joining Akcea, a move expected to facilitate the rapid transition in the ongoing launch preparations. Sarah Boyce, Ionis’ chief business officer will move to Akcea as president and board member. Here extensive, global experience in the life sciences industry will be beneficial to Akcea.